
The current MBX market cap is 261.71M. The company's latest EPS is USD -1.8526 and P/E is -3.99.
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | |
Operating Income | -19.61M | -18.61M | |
Net Income | -18.14M | -15.59M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 0 | 0 |
Operating Income | -25.16M | -35.31M | -68.19M |
Net Income | -26.14M | -32.56M | -61.92M |
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Assets | 282.4M | 268.54M | |
Total Liabilities | 11.03M | 11.09M | |
Total Equity | 271.37M | 257.44M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Total Assets | 45.1M | 84.18M | 268.54M |
Total Liabilities | 3.82M | 4.29M | 11.09M |
Total Equity | -42.61M | -72.47M | 257.44M |
Quarter End | Sep 2024 | Dec 2024 | |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Operating | -38.64M | -54.68M | |
Investing | -93.25M | -160.6M | |
Financing | 234.24M | 234.1M |
Year End December 30 2024 | 2022 | 2023 | 2024 |
---|---|---|---|
USD ($) | USD ($) | USD ($) | |
Operating | -23.12M | -31.98M | -54.68M |
Investing | -11.41M | -30.93M | -160.6M |
Financing | 46.06M | 69.22M | 234.1M |
Market Cap | 261.71M |
Price to Earnings Ratio | -3.99 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 5.01 |
Price to Book Ratio | 0.96 |
Dividend Yield | - |
Shares Outstanding | 33.42M |
Average Volume (1 week) | 444.68k |
Average Volume (1 Month) | 299.14k |
52 Week Change | -65.96% |
52 Week High | 26.19 |
52 Week Low | 4.8069 |
Spread (Intraday) | 0.46 (5.82%) |
Company Name | MBX Biosciences Inc |
Address |
the corporation trust company wilmington, delaware 19801 |
Website | https://www.mbxbio.com. |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.